Halda Therapeutics disclosed initial clinical data from an ongoing study of its RIPTAC small‑molecule platform in prostate cancer, presenting the first human evidence of target engagement and anti‑tumor activity. The startup highlighted translational biomarker responses alongside tumor shrinkage signals in a subset of patients, positioning RIPTACs as a targeted degradation approach that recruits tumor biology to trigger cancer cell death. The data remain early and from a limited cohort, but they establish a clinical pathway for Halda to expand dosing cohorts and refine patient selection criteria.